Secondary hyperaldosteronism

Secondary hyperaldosteronism is a condition characterized by increased aldosterone production sustained by appropriate or inappropriate activation of the renin-angiotensin-aldosterone system (RAAS), typically in response to a reduction in effective arterial blood volume or decreased renal perfusion. Unlike primary hyperaldosteronism, in which aldosterone secretion becomes relatively autonomous and renin is suppressed, in secondary forms the increase in aldosterone is driven by elevated renin and greater availability of angiotensin II, with a feedback architecture that remains, at least conceptually, downstream from the physiological renal stimulus.

From a clinical perspective, secondary hyperaldosteronism is not a single disease but an endocrine phenotype that develops in widely different settings, ranging from renal artery stenosis and renin-dependent disorders to edematous states such as heart failure and cirrhosis with ascites. In these settings, aldosterone contributes to sodium retention and potassium loss, but its clinical significance depends on the underlying cause, the degree of neurohormonal activation and the patient's cardiovascular and renal reserve.

The epidemiology of secondary hyperaldosteronism is intrinsically variable because it reflects the prevalence of conditions that activate the RAAS within the population. A substantial proportion of cases falls within the broad category of renin-dependent secondary hypertension and renal vascular disease. Renal artery stenosis, particularly when caused by atherosclerosis, represents a paradigmatic clinical condition in which reduced renal perfusion triggers increased renin production, followed by increased angiotensin II and aldosterone. The distribution of this condition follows the determinants of systemic atherosclerosis, including advanced age, diabetes, dyslipidemia, smoking and peripheral vascular disease, with risk increasing in parallel with the overall burden of cardiovascular comorbidities.

In addition to renal vascular disorders, there are clinical settings in which RAAS activation is driven by an alteration in effective arterial blood volume. In heart failure, reduced cardiac output and reduced perceived renal perfusion lead to a chronic neurohormonal response in which aldosterone and angiotensin II become mediators of sodium and water retention and cardiovascular remodeling. Similarly, in advanced cirrhosis with splanchnic vasodilation and arterial underfilling, RAAS activation contributes to sodium retention, ascites and dilutional hyponatremia. Nephrotic syndrome and other renal disorders associated with edema may also involve alterations in sodium and volume regulation that, in selected subgroups, are accompanied by increased renin and aldosterone, contributing to the complexity of the clinical presentation.

An additional epidemiological determinant is iatrogenic. The use of diuretics may increase renin and aldosterone in response to natriuresis and volume contraction, with clinical significance depending on the dose, duration and clinical setting, including hypertension, heart failure and cirrhosis. Hypovolemia, gastrointestinal fluid losses and dehydration may also cause transient RAAS hyperactivation that resembles a secondary hyperaldosteronism phenotype, particularly when accompanied by hypokalemia and metabolic alkalosis.

Individual vulnerability depends on the location and nature of the primary disorder. A patient with structural heart disease, chronic kidney disease or advanced liver disease is more likely to develop clinical consequences of aldosterone hyperactivation because hemodynamic and renal compensatory reserve is reduced. In parallel, resistant hypertension, rapid worsening of renal function, refractory edema or recurrent hypokalemia increase the likelihood that secondary hyperaldosteronism is clinically relevant and warrants a targeted diagnostic pathway.

The RAAS is an integrated cascade that connects the kidney, acting as a sensor of perfusion and sodium content, with the regulation of blood pressure and sodium-water balance. Renin secretion by the juxtaglomerular apparatus increases in response to reduced renal perfusion pressure, decreased sodium delivery to the macula densa and beta-adrenergic sympathetic stimulation. Renin converts angiotensinogen into angiotensin I, which is subsequently converted into angiotensin II. Angiotensin II stimulates the adrenal zona glomerulosa to produce aldosterone and also affects vascular tone and glomerular hemodynamics. Within this framework, secondary hyperaldosteronism results from an increased upstream signal, namely excessive renin production or persistent activation of the pathway leading to elevated angiotensin II concentrations.

From an etiological perspective, the most illustrative group includes disorders causing renal hypoperfusion or reduced effective blood flow to one or both kidneys. Renal artery stenosis is the prototype: the ischemic kidney increases renin production, which raises systemic blood pressure and promotes sodium retention. In unilateral stenosis, the pathophysiology may involve a renin-hypersecreting driver kidney and a contralateral kidney attempting to compensate through pressure natriuresis. In bilateral stenosis or a solitary kidney, sodium retention and dependence on angiotensin II to maintain glomerular filtration make the balance between blood pressure control and renal function more fragile. In rare cases, renin overproduction may result from renin-secreting neoplasms or specific renal disorders, producing particularly marked secondary hyperaldosteronism that may be difficult to stabilize.

A second major etiological group is represented by edematous states. In heart failure, reduced cardiac output and perceived renal hypoperfusion induce sympathetic and RAAS activation. Aldosterone increases sodium reabsorption in the distal nephron, leading to volume expansion and increased preload and, over the long term, contributing to myocardial fibrosis, endothelial dysfunction and vascular remodeling. In cirrhosis with ascites, splanchnic vasodilation and reduced effective arterial blood volume lead to persistent neurohormonal activation in which the RAAS and vasopressin promote sodium and water retention, worsening ascites. In nephrotic syndrome, RAAS activation is more heterogeneous. In some subtypes, reduced effective volume and the renal response promote increased renin and aldosterone, whereas in others intrarenal sodium-retaining mechanisms that are not necessarily renin-dependent predominate, with different diagnostic and therapeutic implications.

From a pathophysiological perspective, aldosterone acts by binding to the mineralocorticoid receptor in principal cells of the collecting duct, increasing the expression and activity of epithelial sodium channels and the sodium-potassium adenosine triphosphatase, thereby increasing sodium reabsorption and potassium excretion. In parallel, effects on intercalated cells may promote hydrogen ion secretion, contributing to metabolic alkalosis in patients with significant hypokalemia. However, in secondary hyperaldosteronism, potassium may be normal or even elevated in the presence of advanced renal impairment, treatment with RAAS blockers or other conditions limiting potassium excretion. Biochemical findings are therefore not uniform and must always be interpreted within the clinical context.

A crucial consideration is that secondary hyperaldosteronism often occurs within a neurohormonal activation network in which aldosterone, angiotensin II and the sympathetic nervous system amplify one another. This explains why its clinical effects are not limited to electrolyte balance but also include cardiovascular remodeling, fibrosis, inflammation and endothelial dysfunction. The therapeutic rationale therefore does not merely concern correcting an abnormal laboratory value but reducing a trajectory of risk in patients in whom RAAS hyperactivation is part of the pathogenic mechanism of the underlying disease.

The clinical presentation of secondary hyperaldosteronism is dominated by the underlying disease and by the mechanism through which the renin-angiotensin-aldosterone cascade has been activated. In renin-dependent forms associated with renal artery stenosis or renal hypoperfusion, the presentation may be centered on hypertension that is often difficult to control, sometimes with a relatively rapid onset or sudden worsening of previously stable hypertension. In other patients, the main clinical finding is deterioration of renal function during antihypertensive therapy or in the presence of widespread atherosclerotic disease, a pattern that requires integrated nephrological and vascular assessment.

During the medical history, symptoms related to hypokalemia may be present but are not constant. When aldosterone causes significant potassium loss, the patient may report fatigue, muscle cramps, proximal muscle weakness, paresthesia or palpitations. Polyuria and polydipsia may develop because hypokalemia impairs urinary concentrating ability. However, many patients take diuretics or RAAS blockers that alter biochemical findings and attenuate or mask typical manifestations. Overall clinical and laboratory consistency is therefore more important than any single parameter.

In edematous disorders, the clinical history is often dominated by dyspnea, reduced exercise tolerance and fluid retention in heart failure, or by abdominal distension, weight gain and signs of portal hypertension in decompensated cirrhosis. In these settings, elevated aldosterone contributes to sodium retention and persistence of edema, but the patient experiences a systemic illness in which the endocrine phenotype is one component of a broader neurohormonal system.

On physical examination, patients with renin-dependent hypertension may have elevated blood pressure, signs of hypertensive target-organ damage and, when hypokalemia is severe, muscle weakness. Particular attention should be paid to vascular and cardiac assessment because abdominal bruits, signs of peripheral atherosclerosis and findings consistent with ischemic heart disease increase the likelihood of atherosclerotic renal artery stenosis as the underlying cause. In edematous states, examination may reveal dependent edema, ascites, jugular venous distension and signs of pulmonary congestion, findings that reflect the severity of the underlying disease more than the aldosterone concentration itself.

A clinically important feature is the potential variability of the phenotype over time. Secondary hyperaldosteronism may be intermittent in relation to changes in volume status, sodium intake, intercurrent infections, intensity of diuretic therapy and medication adherence. These fluctuations may produce periods of hypokalemia and alkalosis alternating with phases of apparent biochemical balance. A detailed history of medications, diuretic use, sodium restriction and changes in body weight is therefore often decisive for correct interpretation.

Secondary hyperaldosteronism should be suspected when hypertension or fluid retention is accompanied by evidence of RAAS activation, particularly when the presentation is disproportionate to the previous clinical history or when signs of renal hypoperfusion are present. In patients with resistant hypertension, sudden worsening of blood pressure, unexplained renal impairment or marked fluctuations in renal function in relation to treatment, a renin-dependent cause should be considered a clinical priority.

Suspicion becomes stronger when features suggestive of renal artery stenosis are present, including known systemic atherosclerosis, onset of hypertension at an advanced age, rapid worsening of blood pressure in a previously controlled patient or deterioration of renal function after the introduction of treatments that reduce intraglomerular pressure, particularly in the presence of bilateral stenosis or a solitary kidney. The occurrence of flash pulmonary edema in selected settings of renovascular disease is another clinical sign that should prompt targeted assessment.

In edematous states, suspicion of secondary hyperaldosteronism does not arise primarily from hypertension or hypokalemia but from the underlying pathophysiological mechanism. In heart failure with congestion and a suboptimal diuretic response, or in cirrhosis with refractory ascites, activation of the RAAS and elevated aldosterone are often part of the sodium-retaining mechanism. In these settings, the clinical relevance of the phenotype is reflected in the use of treatments that antagonize mineralocorticoid activity or modulate the RAAS, while balancing the risks of hyperkalemia and renal deterioration.

Secondary hyperaldosteronism must be distinguished from conditions that mimic mineralocorticoid excess without elevated aldosterone, such as certain forms of pseudo-hyperaldosteronism or corticosteroid excess with mineralocorticoid activity. The main clinical and laboratory discriminator is the combination of renin and aldosterone. In secondary hyperaldosteronism, both tend to be elevated, whereas in pseudo-mineralocorticoid states renin is often suppressed and aldosterone may be low. Clinical suspicion is therefore inseparable from timely planning of the appropriate investigations.

The diagnosis of secondary hyperaldosteronism is a two-stage process. The first step is to document a biochemical profile consistent with elevated aldosterone associated with non-suppressed renin. The second is to identify the upstream cause activating the RAAS. The initial evaluation should include electrolytes, renal function, acid-base status, plasma aldosterone and measurement of renin as either plasma renin activity or direct renin concentration. Testing should be performed under pre-analytical conditions that are as controlled as possible, accounting for sodium intake, posture, time of sampling and, above all, medications, because diuretics and RAAS blockers may increase renin and significantly alter interpretation.

In practice, whereas screening for primary hyperaldosteronism focuses on the aldosterone-to-renin ratio in the presence of suppressed renin, the key interpretive feature in secondary hyperaldosteronism is that aldosterone production is sustained by a renin-mediated drive. The aldosterone-to-renin ratio therefore tends not to be elevated as it is in primary forms, and assessment should focus on the pathophysiological consistency between elevated renin, elevated aldosterone and a clinical setting of renal hypoperfusion or reduced effective arterial blood volume.

Diagnostic assessment of secondary hyperaldosteronism

• Biochemical documentation: increased aldosterone with elevated renin or non-suppressed renin, interpreting the results in relation to sodium intake, posture, renal function and concomitant treatments.
• Assessment of the clinical phenotype: renin-dependent hypertension or an edematous state with sodium retention, with evaluation for hypokalemia and metabolic alkalosis when clinically relevant.
• Identification of the upstream cause: distinction between renal hypoperfusion and reduced effective arterial blood volume, including medication history and assessment for heart failure, cirrhosis with ascites, nephrotic syndrome and renal disease.
• Targeted imaging when indicated: assessment of the renal arteries using non-invasive techniques and structural and functional evaluation of cardiac, hepatic and renal disease to identify the main driver of RAAS activation.

Once the renin-aldosterone profile has been defined, the next step is etiological investigation. If the presentation is hypertensive and renin-dependent, attention is directed toward renovascular disease and other causes of renal hypoperfusion. Non-invasive renal artery imaging, including duplex Doppler ultrasonography, computed tomography angiography or magnetic resonance angiography, is selected according to pre-test probability, renal function, local availability and the clinical question. The aim is not merely to document an anatomical stenosis but to determine whether the lesion is hemodynamically significant and consistent with the clinical presentation. In selected complex cases, more advanced investigations, including angiography, may be required, particularly when an interventional strategy is potentially indicated.

When the phenotype is that of an edematous state, diagnosis is integrated with staging and assessment of the underlying disease. In suspected heart failure, electrocardiography, echocardiography, biomarkers and clinical hemodynamic assessment define severity and guide treatment. In cirrhosis with ascites, hepatological evaluation and stratification of the risk of complications determine the therapeutic approach, including sodium management, diuretic therapy and mineralocorticoid receptor antagonism. In nephrotic syndrome, nephrological assessment of the type of lesion and volume profile is essential because RAAS activation and the response to antagonists may differ between subtypes.

Finally, the differential diagnosis should include conditions causing hypokalemia and metabolic alkalosis without a true increase in aldosterone, as well as disorders in which the renin-aldosterone profile is altered by pharmacological interference or advanced renal failure. When results are inconsistent with the expected physiology, measurements often need to be repeated under more controlled conditions, with structured reassessment of medications and sodium intake. Misinterpretation may lead to inappropriate treatment or delay identification of the primary cause.

The classification of secondary hyperaldosteronism is most useful when based on the mechanism activating the RAAS because this determines both the clinical presentation and treatment. A first category includes forms caused by renal hypoperfusion, in which elevated renin is the main driver. This group includes renal artery stenosis, renin-dependent hypertension and rare causes of renin hypersecretion. In these cases, aldosterone acts as an effector of the cascade, and correction of the renal or vascular driver is the intervention most likely to modify the natural history.

A second category includes forms caused by reduced effective arterial blood volume, in which the kidney perceives underfilling even when total body volume is increased. Heart failure and cirrhosis with ascites are the prototypes. RAAS activation is part of a chronic neurohormonal compensatory response that tends to become maladaptive, sustaining sodium and water retention and contributing to cardiovascular remodeling and clinical progression. In these patients, the severity of secondary hyperaldosteronism often parallels the severity of the systemic disease and the difficulty of achieving stable hemodynamic balance.

A third practical category concerns the relationship with medications, particularly diuretics and treatments that modulate the RAAS. Iatrogenic secondary hyperaldosteronism caused by volume depletion or natriuresis is common and may be transient, but it becomes clinically relevant when it causes persistent hypokalemia, alkalosis and blood pressure instability or makes the control of congestion and edema more difficult. In this setting, distinguishing a desired physiological response from excessive maladaptive activation is central to treatment personalization.

Clinical severity may be stratified according to hemodynamic, electrolyte and target-organ effects. Mild forms may present with modest biochemical abnormalities and clinical findings dominated by the underlying disease. More severe forms include resistant hypertension with target-organ damage, progressive renal deterioration, refractory edema or marked hypokalemia associated with arrhythmias and weakness. In these patients, control of the RAAS and mineralocorticoid activity becomes a prognostic determinant but must be balanced against the risks of hyperkalemia and renal vulnerability.

Treatment of secondary hyperaldosteronism cannot be standardized in the same way as treatment of primary forms because the main objective is to reduce RAAS activation by addressing the underlying cause and limiting the effects of aldosterone on sodium, potassium and cardiovascular remodeling. In every clinical setting, the strategy must integrate blood pressure control, volume management and cardiorenal protection, with continuous attention to potassium and renal function.

In forms caused by renal hypoperfusion, treatment depends on the underlying disorder. In patients with renal artery stenosis, optimal medical treatment includes control of atherosclerotic risk factors and antihypertensive treatments that modulate the RAAS when tolerated. However, in significant bilateral stenosis or a solitary kidney, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers must be used cautiously because they may reduce filtration pressure and precipitate deterioration of renal function. In selected patients with refractory hypertension, worsening renal function or specific clinical syndromes, revascularization may be considered after carefully assessing the likelihood of benefit against procedural risks and the patient's overall clinical profile.

In edematous states, treatment is primarily guided by the systemic disease. In heart failure, modulation of the RAAS with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or equivalent strategies, combined with mineralocorticoid receptor antagonists, is part of a therapeutic approach aimed at reducing mortality and hospitalization as well as controlling congestion. In this setting, aldosterone is not only a mediator of sodium retention but also a promoter of fibrosis and remodeling, which explains why mineralocorticoid receptor antagonism has a rationale extending beyond correction of hypokalemia. In cirrhosis with ascites, mineralocorticoid receptor antagonism is a cornerstone of sodium-retention management, often combined with loop diuretics, with continuous monitoring of renal function, sodium and potassium and attention to infectious and circulatory complications.

When secondary hyperaldosteronism is sustained or amplified by diuretic therapy, treatment consists of calibrating the diuretic strategy and correcting electrolyte abnormalities rationally. Potassium correction should not rely exclusively on supplementation because elevated aldosterone promotes ongoing losses. In many patients, it is more effective to reduce the RAAS drive, optimize dietary sodium intake and, when indicated, introduce a mineralocorticoid receptor antagonist at a dose appropriate to the clinical context, while balancing the risk of hyperkalemia, particularly in patients with chronic kidney disease.

A general principle is that therapeutic intervention should be gradual but decisive, with close monitoring during treatment adjustments. Optimal management often requires a multidisciplinary approach because the same aldosterone activation may reflect renal vascular disease, advanced heart disease or decompensated liver disease. In these settings, the quality of care depends on the ability to integrate endocrinology, nephrology, cardiology and hepatology within a coherent and safe clinical pathway.

Follow-up of secondary hyperaldosteronism focuses on three objectives: stabilizing the underlying disease activating the RAAS, preventing electrolyte complications and reducing the cardiovascular and renal consequences of neurohormonal hyperactivation. Because aldosterone is often an indicator of a systemic disorder, surveillance should be structured and proportional to the severity of the clinical condition rather than based only on the hormone concentration.

Laboratory monitoring includes potassium, sodium, bicarbonate and renal function, with more frequent testing after changes in diuretic therapy or the introduction of mineralocorticoid receptor antagonists or RAAS blockers. In many patients, the principal risk is not hypokalemia but iatrogenic hyperkalemia, particularly when renal function is impaired or several treatments that reduce potassium excretion are combined. Interpretation must account for diet, sodium intake and changes in volume status because these factors may rapidly modify renin and aldosterone and therefore alter electrolyte trends.

During follow-up of patients with suspected or established renovascular disease, renal function should be monitored over time together with the blood pressure response to medical treatment. When renal function progressively deteriorates or hypertension remains refractory despite optimal therapy, reassessment of the indication for an interventional strategy may become appropriate. Cardiovascular surveillance is equally important because renovascular disease is often a marker of systemic atherosclerosis and a high risk of clinical events.

In edematous states, follow-up is integrated into the management of the underlying disease. In heart failure, body weight, symptoms of congestion, blood pressure and markers of renal function guide adjustments in diuretic and neurohormonal treatment. In cirrhosis, changes in ascites, urinary sodium excretion, plasma sodium and renal function inform titration of diuretic therapy and management of decompensation. In these settings, routine aldosterone monitoring is not necessarily required, whereas monitoring the clinical and biochemical parameters reflecting system stability is essential.

Follow-up should also include patient education aimed at recognizing signs of dehydration, worsening edema, palpitations or neuromuscular symptoms compatible with potassium disturbances. A clearly defined surveillance pathway reduces the risk of dangerous fluctuations caused by autonomous treatment changes and allows intervention before RAAS hyperactivation results in major clinical events.

The prognosis of secondary hyperaldosteronism depends primarily on the underlying disease and the degree of persistent neurohormonal activation. When RAAS activation is transient and related to reversible conditions, such as correctable volume contraction or an acute phase of illness, the phenotype tends to regress after resolution of the stimulus. By contrast, in chronic disorders such as advanced heart failure, decompensated cirrhosis or atherosclerotic renovascular disease, secondary hyperaldosteronism often indicates an unstable compensatory system and is associated with a higher risk of cardiorenal events.

Electrolyte complications include hypokalemia with weakness, cramps and potential arrhythmic risk, as well as metabolic alkalosis when potassium and hydrogen ion losses are substantial. However, in many patients the most concerning treatment-related complication is hyperkalemia, particularly when mineralocorticoid receptor antagonists and RAAS blockers are combined in the presence of impaired renal function. This requires careful balancing of the benefits of reduced remodeling and volume control against electrolyte risks, with close follow-up during dose titration.

Cardiovascular complications are often related to the underlying disease, but aldosterone amplifies risk through its effects on myocardial fibrosis, vascular stiffness and endothelial dysfunction. In heart failure, RAAS hyperactivation promotes disease progression and worsening congestion, making neurohormonal modulation an important prognostic determinant. In renovascular disease, prognosis is influenced by the risk of systemic atherothrombotic events as well as by the trajectory of renal function, and secondary hyperaldosteronism reflects chronic stimulation of the blood pressure and volume-regulating axis.

From a renal perspective, prognosis depends on the balance between perfusion, intraglomerular pressure and progression of the underlying disease. In bilateral stenosis or a solitary kidney, dependence on angiotensin II to maintain filtration makes some patients vulnerable to renal deterioration after treatment changes. Prevention of iatrogenic complications is therefore an integral component of prognosis. In advanced edematous states, the risk of cardiorenal or hepatorenal syndromes increases when sodium and volume homeostasis becomes difficult to maintain and neurohormonal activation remains elevated despite optimal therapy.

Overall, secondary hyperaldosteronism is a marker of RAAS activation that may be physiologically appropriate but clinically maladaptive. Prognosis improves when the upstream cause is identified early, chronic exposure to excess mineralocorticoid activity is reduced and continuous monitoring prevents electrolyte fluctuations and cardiorenal deterioration, which are the main determinants of adverse outcomes.